Director/PDMR Shareholding
Updated : 13:59
Creo Medical Group plc
("Creo" or the "Company")
Director / PDMR Shareholding
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that on 6 August 2019, Charles Spicer, Non-Executive Chairman, purchased 14,220 ordinary shares of £0.001 each in the capital of the Company ("Ordinary Shares") via his Self-Invested Personal Pension ("SIPP") at a price of 140.64 pence per Ordinary Share.
Following this purchase, Charles Spicer holds 80,010 Ordinary Shares in the Company, representing approximately 0.066% of the Company's issued share capital.
The information below, set out in accordance with the requirements of the MAR, provides further detail.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a) | Name | Charles Spicer | |||
2 | Reason for the notification | ||||
a) | Position/status | Non-Executive Chairman | |||
b)
| Initial notification /Amendment | Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | Creo Medical Group plc | |||
b) | LEI | 213800H188ZDCWWXFA21 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each | |||
|
| ||||
Identification code | GB00BZ1BLL44 | ||||
|
| ||||
b) | Nature of the transaction | Purchase of shares via SIPP | |||
c)
| Price(s) and volume(s) |
|
|
|
|
|
| Price(s) | Volume(s) |
| |
|
| 140.64 pence | 14,220 |
| |
|
|
|
|
| |
d) | Aggregated information |
| |||
|
| ||||
- Aggregated volume | N/A - single transaction | ||||
|
| ||||
- Price |
| ||||
|
| ||||
e) | Date of the transaction | 6 August 2019 | |||
f) | Place of the transaction | London Stock Exchange | |||
Creo Medical Group plc |
|
Richard Rees (CFO) | +44 (0)129 160 6005 |
|
|
Cenkos Securities | +44 (0)20 7397 8900 |
Stephen Keys / Mark Connelly (NOMAD) |
|
Michael Johnson / Russell Kerr (Sales) |
|
|
|
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
Paul McManus | Mob: +44 (0)7980 541 893 |
Lianne Cawthorne | Mob: +44 (0)7515 909 238 |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, investors.creomedical.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.